Company intelligence / Profile preview

Immune System Therapeutics

Sydney, New South Wales, Australiaimmunostherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

As of the early 2010s, Immune System Therapeutics developed monoclonal antibodies for blood cancers and autoimmune diseases. Its lead candidate, MDX‑1097 targeting kappa myeloma antigen for multiple myeloma, showed encouraging safety and efficacy signals in early clinical trials and entered Phase 2 studies. The company also held robust patents on its drug class but has not reported recent clinical results publicly since that time.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Drug pipeline

1 asset

IOS-1002

Phase 1

Indications: Advanced solid tumors

Beyond the preview

Go deeper on Immune System Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune System Therapeutics.

Explore the full profile